Finanzen von Aeon Biopharma Inc (AEON)AEONAeon Biopharma Inc

In the context of the broader market, AEON competes directly with industry leaders such as HIND and NRSN. With a market capitalization of $15.67M, it holds a significant position in the sector. When comparing efficiency, AEON's gross margin of N/A stands against HIND's 33.57% and NRSN's N/A. Such benchmarking helps identify whether Aeon Biopharma Inc is trading at a premium or discount relative to its financial performance.

Aeon Biopharma has shown a volatile financial performance with significant net losses, including -11,793,000 USD in Q1 2026 and a forward P/E of 1.1577, indicating potential for future earnings growth if the company can stabilize.